Kodiak Sciences Inc. (NASDAQ:KOD) Forecasted to Earn FY2026 Earnings of $1.28 Per Share

Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) – Capital One Financial upped their FY2026 EPS estimates for shares of Kodiak Sciences in a research note issued on Friday, May 19th. Capital One Financial analyst Z. Jallah now expects that the company will earn $1.28 per share for the year, up from their prior estimate of $1.17. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($4.98) per share. Capital One Financial also issued estimates for Kodiak Sciences’ FY2027 earnings at $4.74 EPS.

Separately, JPMorgan Chase & Co. reduced their target price on Kodiak Sciences from $12.00 to $10.00 and set a “neutral” rating on the stock in a report on Tuesday, April 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Kodiak Sciences presently has an average rating of “Hold” and an average price target of $12.86.

Kodiak Sciences Price Performance

Kodiak Sciences stock opened at $5.91 on Monday. The stock has a fifty day moving average price of $5.05 and a two-hundred day moving average price of $6.55. Kodiak Sciences has a 52-week low of $4.25 and a 52-week high of $12.80. The firm has a market capitalization of $309.39 million, a P/E ratio of -1.00 and a beta of 1.76.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Braidwell LP purchased a new position in shares of Kodiak Sciences in the 4th quarter worth $6,546,000. BlackRock Inc. grew its position in Kodiak Sciences by 20.5% in the first quarter. BlackRock Inc. now owns 3,435,960 shares of the company’s stock worth $26,526,000 after acquiring an additional 584,762 shares in the last quarter. Bruce & Co. Inc. purchased a new position in Kodiak Sciences in the first quarter worth about $2,933,000. Krensavage Asset Management LLC purchased a new position in Kodiak Sciences in the first quarter worth about $2,849,000. Finally, Walleye Capital LLC grew its position in Kodiak Sciences by 1,904.5% in the first quarter. Walleye Capital LLC now owns 356,093 shares of the company’s stock worth $2,749,000 after acquiring an additional 338,328 shares in the last quarter. Institutional investors own 80.02% of the company’s stock.

About Kodiak Sciences

(Get Rating)

Kodiak Sciences, Inc is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD.